Placeholder Banner

BIO Comments on FDA Draft Guidance on Rare Diseases: Natural History Studies for Drug Development

May 24, 2019

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Rare Diseases: Natural History Studies for Drug Development.

BIO says the guidance is as an important communication tool for the FDA and Sponsors. It ensures Sponsors have the appropriate information for developing new therapies for patients with rare diseases ­– especially since many rare diseases do not have FDA-approved treatment.

BIO provides recommendations on how to improve natural history studies so the FDA can have robust data for making regulatory decisions, as well as how to improve the guidance. BIO recommends the draft guidance align with other draft guidance covering natural history studies, like Rare Diseases: Common Issues in Drug Development

 

Download Full Comments Below
BIO Comment Letter Natural History Studies Rare Disease Drug Development FDA–2017-D-0481
Read the full comment letter below
Discover More
January 7, 2020 Re: Docket No. FDA–2019-N-3453: Promoting Effective Drug Development Programs: Opportunities and Priorities for the Food and Drug Administration's Office of New Drugs Dear Sir/Madam: The Biotechnology Innovation Organization (BIO…
January 4, 2020 Re: Docket No. FDA–2019-N-5157: 2019 Public Meeting on Center for Drug Evaluation and Research Standard Core Sets: Clinical Outcome Assessments and Endpoints Grant Program. Dear Sir/Madam: The Biotechnology Innovation Organization…
On December 16, 2019, the Biotechnology Innovation Organization (BIO) provided comments on the Food and Drug Administration’s (FDA’s) Notice to Public of Website Location of CDRH Fiscal Year 2020 Proposed Guidance Development; In Vitro…